Skip to main content

Health condition · Clinically reviewed

Cholangiocarcinoma, anatomic subtypes, molecular profiling and modern systemic therapy.

The medical term for bile duct cancer. Care is now shaped by anatomic location, molecular alterations and access to specialist HPB expertise. For a plainer patient-facing overview see our bile duct cancer guide.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO, BSG and peer-reviewed hepatobiliary sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern practice including TOPAZ-1 durvalumab, KEYNOTE-966 pembrolizumab, FGFR2 and IDH1 targeted therapies.

Key facts

Cholangiocarcinoma at a glance.

The essentials, in plain English: what it is, the anatomic subtypes, the main risk drivers and where cure is possible.

  • What it is

    An adenocarcinoma of the biliary epithelium (the cells lining the bile ducts). The clinical name for bile duct cancer.

  • Anatomic types

    Intrahepatic (iCCA, 10 to 20 per cent), perihilar or Klatskin (50 to 60 per cent) and distal extrahepatic (20 to 30 per cent).

  • Bismuth-Corlette

    Perihilar tumours are subclassified I to IV by the extent of ductal involvement, which drives resection planning.

  • Key risk factors

    Primary sclerosing cholangitis (around 400x baseline risk), hepatolithiasis, chronic viral hepatitis, cirrhosis, liver fluke, choledochal cyst.

  • Molecular era

    Actionable alterations in FGFR2, IDH1, HER2, BRAF, NTRK, RET and MSI-high status now shape systemic therapy.

  • Curative option

    Surgery, and in selected early perihilar disease liver transplantation under the Mayo protocol, offer the only chance of cure.

Why this guide matters

Anatomy, molecules and MDT care shape everything.

Cholangiocarcinoma is uncommon but its management has been transformed in the last five years. Three ideas run through this page.

  • Anatomy dictates surgery

    Intrahepatic, perihilar (Bismuth-Corlette I to IV) and distal disease each demand a very different operation and specialist team.

  • Molecular profiling is now mandatory

    FGFR2, IDH1, HER2, NTRK, RET, BRAF and MSI status unlock targeted and immune therapies at diagnosis of advanced disease.

  • HPB MDT centres save lives

    Outcomes are meaningfully better when care is led by a designated hepatobiliary MDT with hepatology, oncology and interventional radiology.

How the diagnosis is made

From first jaundice to a molecular map.

The steps a UK hepatobiliary team will normally follow, in order, so you know what to expect and why each investigation matters.

  1. 01

    Assessing

    Symptom review and LFTs

    Painless jaundice, pruritus, weight loss, fatigue and RUQ pain trigger a full obstructive liver-function panel.

  2. 02

    Assessing

    CA 19-9 and CEA

    Tumour markers support the picture and provide a baseline for monitoring, but neither is diagnostic on its own.

  3. 03

    Assessing

    Ultrasound then MRI with MRCP

    US screens for duct dilatation. MRI with MRCP is the gold standard for mapping tumour extent, vascular anatomy and biliary tree.

  4. 04

    Confirming

    CT staging of chest and abdomen

    Multiphase CT defines resectability, nodal disease and distant spread. PET-CT is used selectively.

  5. 05

    Confirming

    ERCP with brush cytology

    Direct sampling with IDUS, SpyGlass cholangioscopy and targeted biopsy confirms histology and allows stenting.

  6. 06

    Confirming

    Staging laparoscopy

    For intrahepatic and perihilar disease, laparoscopy detects peritoneal spread missed on cross-sectional imaging.

  7. 07

    Planning

    Molecular profiling

    Comprehensive tumour profiling (FGFR2, IDH1, HER2, BRAF, NTRK, RET, MSI) is now mandatory and guides targeted therapy.

Typical timeline: from first jaundice to full MDT plan in a matter of weeks at a specialist HPB centre.

Symptoms

What cholangiocarcinoma actually looks like.

The classic obstructive picture of painless jaundice, pruritus and weight loss, plus the features that mean it is time to act quickly.

  • Painless jaundice

    Yellowing of skin and sclera without pain, often the first and most specific sign of biliary obstruction.

  • Pruritus

    Intense generalised itching from bile salt accumulation, often preceding visible jaundice.

  • Pale stools and dark urine

    Classic obstructive pattern from absent bilirubin in the gut and renal excretion of conjugated bilirubin.

  • Weight loss and fatigue

    Unintentional weight loss, poor appetite and profound tiredness are common at diagnosis.

  • RUQ pain or discomfort

    A dull ache under the right ribs, often late and sometimes associated with a palpable liver edge.

  • Cholangitis

    Fever, rigors and jaundice (Charcot triad) point to infected obstructed bile and need urgent drainage.

  • Late abdominal mass

    A palpable liver, gallbladder (Courvoisier sign) or upper-abdominal mass suggests advanced disease.

  • Red flag - PSC with new jaundice

    Any patient with primary sclerosing cholangitis and a change in liver tests or new jaundice needs urgent cholangiocarcinoma workup.

Treatment

How cholangiocarcinoma is treated in the UK.

Surgery and, in selected cases, transplantation offer cure. For unresectable disease, chemo-immunotherapy and targeted agents now meaningfully extend life.

  • Curative surgery

    Hepatectomy with lymphadenectomy for iCCA; extended hepatectomy plus caudate lobectomy and Roux-en-Y hepaticojejunostomy for perihilar; Whipple for distal disease.

  • Liver transplantation

    For selected early perihilar cholangiocarcinoma under the Mayo protocol combining neoadjuvant chemoradiotherapy and transplant at specialist centres.

  • Adjuvant capecitabine

    Six months of oral capecitabine after resection is the standard of care based on the BILCAP trial.

  • Gem-Cis-Durvalumab

    First-line for unresectable or metastatic disease. Gemcitabine plus cisplatin plus durvalumab (TOPAZ-1) is now practice-changing.

  • Gem-Cis-Pembrolizumab

    An alternative first-line combination, adding pembrolizumab to gemcitabine and cisplatin (KEYNOTE-966).

  • FOLFOX (2nd-line)

    Second-line chemotherapy for fit patients after progression, supported by the ABC-06 trial.

  • Targeted therapy

    Pemigatinib, infigratinib or futibatinib for FGFR2 fusions; ivosidenib for IDH1 mutations; larotrectinib or entrectinib for NTRK; selpercatinib for RET; dabrafenib-trametinib for BRAF V600E; trastuzumab-tucatinib for HER2; pembrolizumab for MSI-high.

  • Locoregional therapy

    TARE (Y-90 radioembolisation), TACE, radiofrequency ablation, external-beam radiotherapy, photodynamic therapy and endoluminal ablation for liver-dominant or biliary disease.

Related treatments and services

What this guide is based on

The sources behind every claim on this page.

UK and international guidance and pivotal peer-reviewed trials, current at the time of last review.

Key references

Guidelines, standards and trials we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your hepatobiliary team knows your imaging, molecular profile and fitness, and can tell you which parts apply to you. If in doubt, ask.

  • NICE. Cholangiocarcinoma pathway and hepatobiliary cancer guidance.

  • ESMO. Biliary tract cancer clinical practice guidelines (updated).

  • British Society of Gastroenterology (BSG). Guidelines on the diagnosis and management of cholangiocarcinoma.

  • Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). NEJM Evid, 2022.

  • Kelley RK et al. Pembrolizumab plus gemcitabine and cisplatin (KEYNOTE-966). Lancet, 2023.

  • Primrose JN et al. Capecitabine after resection (BILCAP). Lancet Oncol, 2019.

  • Lamarca A et al. Second-line FOLFOX (ABC-06). Lancet Oncol, 2021.

  • AMMF - The Cholangiocarcinoma Charity (UK). Patient information and support.

Red flags

When cholangiocarcinoma needs urgent attention.

These situations warrant same-day or same-week specialist review. Do not wait to see if things settle on their own.

  • PSC with new jaundice

    Any new jaundice, dominant stricture or rising CA 19-9 in primary sclerosing cholangitis needs urgent hepatobiliary review.

  • Cholangitis

    Fever, rigors and jaundice suggest infected obstructed bile - a surgical emergency requiring urgent drainage and antibiotics.

  • Rapid weight loss

    Unexplained rapid weight loss with abnormal liver enzymes warrants same-week imaging and specialist referral.

  • Post-ERCP deterioration

    Worsening pain, sepsis or bleeding after ERCP needs immediate hospital assessment.

  • Uncontrolled pruritus

    Severe itching that disturbs sleep signals inadequate biliary drainage and needs urgent review.

  • Ascites or portal hypertension

    New ascites or variceal bleeding in known cholangiocarcinoma may reflect vascular invasion or decompensation.

  • Choledochal cyst

    Congenital choledochal cysts carry a lifetime malignancy risk and warrant surgical excision.

  • Hepatolithiasis

    Recurrent intrahepatic stones cause chronic inflammation and elevate cholangiocarcinoma risk - surveillance matters.

  • Occupational and environmental

    Thorotrast exposure (historical) and endemic liver fluke infection (Opisthorchis, Clonorchis in SE Asia) are recognised risks.

Living with it

A demanding diagnosis, with real support.

Four things that make the biggest difference day to day: a specialist team, protecting nutrition, controlling pruritus and pain, and connecting with the right charities.

A quiet reminder

Ask for a HPB centre and molecular profiling early.

Both are standard of care and both can meaningfully change the treatment plan. It is reasonable to ask.

  1. 01 Team

    A specialist HPB centre

    Care should be led by a hepatobiliary MDT with hepatology, oncology, interventional radiology and a specialist HPB nurse.

  2. 02 Nutrition

    Protect weight and muscle

    Early dietitian input, pancreatic enzyme replacement where needed and small frequent meals protect strength through treatment.

  3. 03 Symptoms

    Pruritus and pain plans

    Effective biliary drainage, bile-acid sequestrants and a stepped pain plan make a real difference to daily life.

  4. 04 Support

    AMMF and Cancer Research UK

    The AMMF Cholangiocarcinoma Charity and Cancer Research UK offer patient information, peer support and access to trials.

Frequently asked

Everything we get asked about cholangiocarcinoma.

Quick answers on subtypes, molecular testing, first-line therapy and liver transplantation.

  • What is cholangiocarcinoma?

    An adenocarcinoma arising from the epithelial cells that line the bile ducts inside or outside the liver. It is the medical term for bile duct cancer and is grouped as intrahepatic, perihilar (Klatskin) or distal extrahepatic based on where it arises.

  • How is it different from bile duct cancer?

    They are the same disease. Cholangiocarcinoma is the precise medical term used by clinicians and researchers, while bile duct cancer is the patient-facing name. This page focuses on the specialist terminology, molecular subtypes and current systemic therapy landscape.

  • What are the main risk factors?

    Primary sclerosing cholangitis is the strongest known Western risk factor, carrying around a 400-fold increase over baseline. Others include hepatolithiasis, chronic hepatitis B and C, cirrhosis, choledochal cyst, Caroli disease, inflammatory bowel disease, obesity, type 2 diabetes, smoking, alcohol and, in South East Asia, liver fluke infection.

  • Why does molecular profiling matter?

    Around half of intrahepatic cholangiocarcinomas carry an actionable alteration. FGFR2 fusions, IDH1 mutations, HER2 amplification, MSI-high status, NTRK, RET and BRAF V600E now have licensed targeted or immunotherapy options that meaningfully change outcomes. Profiling is considered mandatory at diagnosis of advanced disease.

  • What is TOPAZ-1 and why is it important?

    TOPAZ-1 was a phase 3 trial published in 2022 that added the anti-PD-L1 antibody durvalumab to first-line gemcitabine and cisplatin for advanced biliary tract cancer. It improved overall survival and became the new first-line standard, alongside the pembrolizumab combination from KEYNOTE-966.

  • Is liver transplantation ever an option?

    Yes, for carefully selected patients with early, unresectable perihilar cholangiocarcinoma. Under the Mayo protocol, neoadjuvant chemoradiotherapy is followed by transplantation at specialist centres, with encouraging long-term survival in appropriate candidates.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.